Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1988 Apr;131(1):102–111.

Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.

H J Schuurman 1, W Huppes 1, L F Verdonck 1, J Van Baarlen 1, J A Van Unnik 1
PMCID: PMC1880564  PMID: 3258475

Abstract

In a retrospective analysis the authors studied the relation between the immunologic phenotype of B-cell non-Hodgkin's lymphoma (NHL) and disease-free survival. The phenotype included immunoglobulin isotypes; B-cell maturation/differentiation antigens of clusters of differentiation CD9, CD10, CD19-24, CD37, CD38; T-lymphocyte antigens in CD5-7; HLA-DR; peanut agglutinin binding capacity; terminal deoxynucleotidyl transferase; the activation marker CD25 (interleukin-2 receptor); and the proliferation marker transferrin receptor. The phenotype and clinical data were available for 109 patients. Two patients underwent bone marrow transplantation, and 15 patients (with low or intermediate grade NHL) did not receive treatment intended to achieve complete remission. These 17 cases were excluded from the analysis. For individual markers, CD23 expression was associated with a longer actuarial disease-free survival (50% survival in CD23-positive cases was 40 months; and in CD23-negative cases, 16 months; P = 0.01). Among the total study population of 92 patients, this finding applied in particular to those with a low-grade malignancy according to the Kiel classification (P = 0.03). In high-grade NHL (Kiel classification) the absence of CD38 or presence of CD24 on tumor cells correlated with a higher degree of disease-free survival (P values 0.009 and 0.04, respectively). For a combination of five CD markers associated with stages in physiologic B-lymphocyte maturation/differentiation (CD9, CD10, CD21-23), the lowest measure of disease-free survival was observed where NHLs were at an immature stage, and the greatest extent of survival where NHLs were associated with a resting B-cell stage (P = 0.006). These statistical significances aside, the detailed immunologic phenotyping has relatively little prognostic value when compared with that of the malignancy grade assessed by conventional histopathology.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage R. J., Cawley J. C. Normal and certain leukaemic B cells express IL-2 receptors without in vitro activation. Clin Exp Immunol. 1986 Feb;63(2):298–302. [PMC free article] [PubMed] [Google Scholar]
  2. Bloomfield C. D., Gajl-Peczalska K. J., Frizzera G., Kersey J. H., Goldman A. I. Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. N Engl J Med. 1979 Sep 6;301(10):512–518. doi: 10.1056/NEJM197909063011002. [DOI] [PubMed] [Google Scholar]
  3. Bonnefoy J. Y., Aubry J. P., Peronne C., Wijdenes J., Banchereau J. Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE. J Immunol. 1987 May 1;138(9):2970–2978. [PubMed] [Google Scholar]
  4. Boyd A. W., Fisher D. C., Fox D. A., Schlossman S. F., Nadler L. M. Structural and functional characterization of IL 2 receptors on activated human B cells. J Immunol. 1985 Apr;134(4):2387–2392. [PubMed] [Google Scholar]
  5. Brittinger G., Bartels H., Common H., Dühmke E., Fülle H. H., Gunzer U., Gyenes T., Heinz R., König E., Meusers P. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol. 1984 Jul-Sep;2(3):269–306. doi: 10.1002/hon.2900020306. [DOI] [PubMed] [Google Scholar]
  6. Carde P., Burgers J. M., van Glabbeke M., Hayat M., Cosset J. M., Somers R., Sizoo W., Qasim M. M., Lefur R., Abbatucci J. S. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother Oncol. 1984 Dec;2(4):301–312. doi: 10.1016/s0167-8140(84)80072-9. [DOI] [PubMed] [Google Scholar]
  7. Collins R. D. Lymph node examination. What is an adequate workup? Arch Pathol Lab Med. 1985 Sep;109(9):797–799. [PubMed] [Google Scholar]
  8. Cossman J., Jaffe E. S., Fisher R. I. Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features. Cancer. 1984 Oct 1;54(7):1310–1317. doi: 10.1002/1097-0142(19841001)54:7<1310::aid-cncr2820540714>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  9. Costa A., Bonadonna G., Villa E., Valagussa P., Silvestrini R. Labeling index as a prognostic marker in non-Hodgkin's lymphomas. J Natl Cancer Inst. 1981 Jan;66(1):1–5. [PubMed] [Google Scholar]
  10. Drexler H. G., Menon M., Sagawa K., Tatsumi E., Koshiba H., Koishi T., Minato K., Sugimoto T., Saito M., Morita M. Phenotyping of malignant hematopoietic cells. Analysis of 1200 cases of leukemia-lymphoma. Blut. 1986 Feb;52(2):99–109. doi: 10.1007/BF00321072. [DOI] [PubMed] [Google Scholar]
  11. Foon K. A., Todd R. F., 3rd Immunologic classification of leukemia and lymphoma. Blood. 1986 Jul;68(1):1–31. [PubMed] [Google Scholar]
  12. Gordon J., Webb A. J., Guy G. R., Walker L. Triggering of B lymphocytes through CD23: epitope mapping and studies using antibody derivatives indicate an allosteric mechanism of signalling. Immunology. 1987 Apr;60(4):517–521. [PMC free article] [PubMed] [Google Scholar]
  13. Gordon J., Webb A. J., Walker L., Guy G. R., Rowe M. Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor. Eur J Immunol. 1986 Dec;16(12):1627–1630. doi: 10.1002/eji.1830161225. [DOI] [PubMed] [Google Scholar]
  14. Greaves M. F., Chan L. C., Furley A. J., Watt S. M., Molgaard H. V. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986 Jan;67(1):1–11. [PubMed] [Google Scholar]
  15. Habeshaw J. A., Lister T. A., Stansfeld A. G., Greaves M. F. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983 Mar 5;1(8323):498–501. doi: 10.1016/s0140-6736(83)92191-8. [DOI] [PubMed] [Google Scholar]
  16. Holte H., Davies C. D., Kvaløy S., Smeland E. B., Foss-Abrahamsen A., Kaalhus O., Marton P. F., Godal T. The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer. 1987 May 15;39(5):590–594. doi: 10.1002/ijc.2910390508. [DOI] [PubMed] [Google Scholar]
  17. Horning S. J., Doggett R. S., Warnke R. A., Dorfman R. F., Cox R. S., Levy R. Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. Blood. 1984 May;63(5):1209–1215. [PubMed] [Google Scholar]
  18. Jung L. K., Hara T., Fu S. M. Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1597–1602. doi: 10.1084/jem.160.5.1597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kikutani H., Suemura M., Owaki H., Nakamura H., Sato R., Yamasaki K., Barsumian E. L., Hardy R. R., Kishimoto T. Fc epsilon receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching. J Exp Med. 1986 Nov 1;164(5):1455–1469. doi: 10.1084/jem.164.5.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Krueger G. R., Medina J. R., Klein H. O., Konrads A., Zach J., Rister M., Janik G., Evers K. G., Hirano T., Kitamura H. A new working formulation of non-Hodgkin's lymphomas. A retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications. Cancer. 1983 Sep 1;52(5):833–840. doi: 10.1002/1097-0142(19830901)52:5<833::aid-cncr2820520515>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  21. Kvaløy S., Langholm R., Kaalhus O., Michaelsen T., Funderud S., Foss Abrahamsen A., Godal T. Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer. 1984 Feb 15;33(2):173–177. doi: 10.1002/ijc.2910330204. [DOI] [PubMed] [Google Scholar]
  22. Laurent G., Al Saati T., Olive D., Laurent J. C., Poncelet P., Delsol G. Expression of Tac antigen in B cell lymphomas. Clin Exp Immunol. 1986 Aug;65(2):354–362. [PMC free article] [PubMed] [Google Scholar]
  23. Mason D. Y. A new look at lymphoma immunohistology. Am J Pathol. 1987 Jul;128(1):1–4. [PMC free article] [PubMed] [Google Scholar]
  24. Mittler R., Rao P., Olini G., Westberg E., Newman W., Hoffmann M., Goldstein G. Activated human B cells display a functional IL 2 receptor. J Immunol. 1985 Apr;134(4):2393–2399. [PubMed] [Google Scholar]
  25. Oudemans P. B., Brutel de la Rivière G., Hart G. A., van Heerde P., Scholte G., Vroom T. M. Determination of transferrin receptors on frozen sections of malignant B-cell lymphomas by immunofluorescence with a monoclonal antibody. Cancer. 1986 Sep 15;58(6):1252–1259. doi: 10.1002/1097-0142(19860915)58:6<1252::aid-cncr2820580613>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  26. Picker L. J., Weiss L. M., Medeiros L. J., Wood G. S., Warnke R. A. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol. 1987 Jul;128(1):181–201. [PMC free article] [PubMed] [Google Scholar]
  27. Porwit-Ksiazek A., Mioduszewska O. Clinical significance of histologic (Kiel) classification combined with immunologic definition of malignant lymphoma. Neoplasma. 1983;30(2):173–180. [PubMed] [Google Scholar]
  28. Rudders R. A., Ahl E. T., Jr, DeLellis R. A. Surface marker and histopathologic correlation with long-term survival in advanced large-cell non-Hodgkin's lymphoma. Cancer. 1981 Mar 15;47(6):1329–1335. doi: 10.1002/1097-0142(19810315)47:6<1329::aid-cncr2820470616>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  29. Schuurman H. J., Kluin P. M., de Gast G. C., Kater L. HNK-1+ cells in non-Hodgkin's lymphoma: lack of relation with transferrin receptor expression on malignant cells. Br J Cancer. 1985 Feb;51(2):171–177. doi: 10.1038/bjc.1985.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schuurman H. J., van Baarlen J., Huppes W., Lam B. W., Verdonck L. F., van Unnik J. A. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology. Am J Pathol. 1987 Oct;129(1):140–151. [PMC free article] [PubMed] [Google Scholar]
  31. Stathopoulos G., Kay H. E., Hamlin I. M., McKay A. M. Surface characteristics of lymphoma cells in relation to treatment, response and survival. Eur J Cancer. 1978 May;14(5):479–483. doi: 10.1016/0014-2964(78)90249-9. [DOI] [PubMed] [Google Scholar]
  32. Stein H., Lennert K., Feller A. C., Mason D. Y. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res. 1984;42:67–147. doi: 10.1016/s0065-230x(08)60456-x. [DOI] [PubMed] [Google Scholar]
  33. Sun T., Susin M. A practical approach to immunophenotyping of lymphomas. Comparison of immunohistologic and immunocytologic techniques. Ann Clin Lab Sci. 1987 Jan-Feb;17(1):14–26. [PubMed] [Google Scholar]
  34. Tsudo M., Uchiyama T., Uchino H. Expression of Tac antigen on activated normal human B cells. J Exp Med. 1984 Aug 1;160(2):612–617. doi: 10.1084/jem.160.2.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tubbs R. R., Fishleder A., Weiss R. A., Savage R. A., Sebek B. A., Weick J. K. Immunohistologic cellular phenotypes of lymphoproliferative disorders. Comprehensive evaluation of 564 cases including 257 non-Hodgkin's lymphomas classified by the International Working Formulation. Am J Pathol. 1983 Nov;113(2):207–221. [PMC free article] [PubMed] [Google Scholar]
  36. Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Warnke R. A., Rouse R. V. Limitations encountered in the application of tissue section immunodiagnosis to the study of lymphomas and related disorders. Hum Pathol. 1985 Apr;16(4):326–331. doi: 10.1016/s0046-8177(85)80226-4. [DOI] [PubMed] [Google Scholar]
  38. Warnke R., Miller R., Grogan T., Pederson M., Dilley J., Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Engl J Med. 1980 Aug 7;303(6):293–300. doi: 10.1056/NEJM198008073030601. [DOI] [PubMed] [Google Scholar]
  39. Yukawa K., Kikutani H., Owaki H., Yamasaki K., Yokota A., Nakamura H., Barsumian E. L., Hardy R. R., Suemura M., Kishimoto T. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (Fc epsilon R) on lymphocytes. J Immunol. 1987 Apr 15;138(8):2576–2580. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES